$1.42
+0.05 (+3.65%)
Open$1.37
Previous Close$1.37
Day High$1.49
Day Low$1.36
52W High$9.64
52W Low$4.95
Volume—
Avg Volume153.9K
Market Cap7.33M
P/E Ratio—
EPS$-1.54
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+709.9% upside
Current
$1.42
$1.42
Target
$11.50
$11.50
$7.99
$11.50 avg
$12.09
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 987.4K | 951.3K | 938.4K |
| Net Income | -74,062 | -66,038 | -67,407 |
| Profit Margin | -7.5% | -6.9% | -7.2% |
| EBITDA | -123,235 | -109,691 | -102,490 |
| Free Cash Flow | -44,936 | -40,091 | -30,740 |
| Rev Growth | +23.6% | +13.9% | +9.1% |
| Debt/Equity | 1.06 | 0.89 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |